ArticleAnnals of hematology2025

Real-world data of siltuximab for Chinese patients with iMCD: combination with BCD regimen as a potential approach for severe cases.

Si-Yuan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.